NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a subcutaneous injection for the potential treatment of congenital adrenal hyperplasia (CAH).

NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a subcutaneous injection for the potential treatment of congenital adrenal hyperplasia (CAH).

Neurocrine Biosciences' potential shines with robust assets, strong pipeline, and growth opportunities. Learn more about NBIX ...

New indication added for selection of patients for amyloid-directed therapiesQuantitative image analysis addedPrevious limitations of use removed Amyloid, a naturally occurring protein, can accumulate ...

The hypothalamus secretes corticotropin releasing factor, which acts on the anterior pituitary, where it stimulates the secretion of adrenocorticotropin (ACTH).

Corticotropin-releasing factor (CRF) neuron activity in the medial prefrontal cortex (mPFC) specifically modulates the influence of affective past experience on emotional reactions to others ...

SAN DIEGO, June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, ...

News provided by Mallinckrodt plc Jun 18, 2025, 6:48 AM ET – Survey findings showed a majority of participants had a favorable experience injecting Acthar Gel via SelfJect, with a high level of ...

The single-rod, etonogestrel-releasing, subdermal implant (ENG implant) is the most effective, long-acting reversible method of contraception available. The failure rate of the ENG implant is 0.05 ...